1. Physiologically based pharmacokinetic modeling in regulatory science: an update from the U.S. Food and Drug Administration's Office of Clinical Pharmacology;Grimstein M;J Pharm Sci,2019
2. 21 C.F.R. 201.56(a)(1): Requirements on content and format of labeling for human prescription drug and biological products.https://www.ecfr.gov/cgi-bin/text-idx?SID=c2a78114892db0881313acb4203a3359&mc=true&node=pt21.4.201&rgn=div5#se21.4.201_156. Accessed October 26 2020.
3. US Food and Drug Administration.Guidance for Industry: Clinical Pharmacology Labeling for Human Prescription Drug and Biological Products ‐ Content and Format.https://www.fda.gov/media/74346/download. Published 2016. Accessed October 26 2020.
4. US Food and Drug Administration.Model‐Informed Drug Development Pilot Program.https://www.fda.gov/drugs/development-resources/model-informed-drug-development-pilot-program. Accessed October 26 2020.
5. US Food and Drug Administration.NDA 207924 Baricitinib Clinical Pharmacology and Biopharmaceutics Review(s).https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/207924Orig1s000ClinPharmR.pdf. Published 2018. Accessed October 26 2020.